Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

 
• By Joseph Haas
  
Bacteria
Summit thinks narrow-spectrum therapy is the best way to fight C. diff infections

More from Clinical Trials

More from R&D